314 related articles for article (PubMed ID: 9749589)
21. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group.
Arch Neurol; 1989 Oct; 46(10):1052-60. PubMed ID: 2508608
[TBL] [Abstract][Full Text] [Related]
22. Selegiline slows the progression of the symptoms of Parkinson disease.
Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
[TBL] [Abstract][Full Text] [Related]
23. Can we differentiate symptomatic and neuroprotective effects in parkinsonism? The dopamine agonist lisuride delays the need for levodopa therapy to a similar extent as reported for deprenyl.
Runge I; Horowski R
J Neural Transm Park Dis Dement Sect; 1991; 3(4):273-83. PubMed ID: 1772580
[TBL] [Abstract][Full Text] [Related]
24. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
25. Recent advances in Parkinson's disease.
Vécsei L
Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
[No Abstract] [Full Text] [Related]
26. Parkinson's disease. Diagnosis and the initiation of therapy.
Bhat V; Weiner WJ
Minerva Med; 2005 Jun; 96(3):145-54. PubMed ID: 16175158
[TBL] [Abstract][Full Text] [Related]
27. Treatment possibilities of Alzheimer's disease.
Miklya I; Gaszner P
Neuropsychopharmacol Hung; 2004 Dec; 6(4):200-9. PubMed ID: 15825676
[TBL] [Abstract][Full Text] [Related]
28. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group.
Kieburtz K; McDermott M; Como P; Growdon J; Brady J; Carter J; Huber S; Kanigan B; Landow E; Rudolph A
Neurology; 1994 Sep; 44(9):1756-9. PubMed ID: 7936311
[TBL] [Abstract][Full Text] [Related]
29. Neuroprotective clinical strategies for Parkinson's disease.
Shoulson I
Ann Neurol; 1992; 32 Suppl():S143-5. PubMed ID: 1510374
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group.
Arch Neurol; 1995 Mar; 52(3):237-45. PubMed ID: 7872875
[TBL] [Abstract][Full Text] [Related]
31. Neuroprotective therapy for Parkinson's disease.
Koller WC
Exp Neurol; 1997 Mar; 144(1):24-8. PubMed ID: 9126147
[TBL] [Abstract][Full Text] [Related]
32. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
33. Deprenyl and levodopa and Parkinson's disease progression.
Fowler JS; Fazzini E; Volkow ND
Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
[No Abstract] [Full Text] [Related]
34. Freezing of gait in PD: prospective assessment in the DATATOP cohort.
Giladi N; McDermott MP; Fahn S; Przedborski S; Jankovic J; Stern M; Tanner C;
Neurology; 2001 Jun; 56(12):1712-21. PubMed ID: 11425939
[TBL] [Abstract][Full Text] [Related]
35. [Neuroprotective and neurorestorative therapy in Parkinson's disease].
Jiménez-Jiménez FJ; Molina JA
Rev Neurol; 1997 Aug; 25 Suppl 2():S185-93. PubMed ID: 9280687
[TBL] [Abstract][Full Text] [Related]
36. Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group.
LeWitt PA
Acta Neurol Scand Suppl; 1991; 136():79-86. PubMed ID: 1801542
[TBL] [Abstract][Full Text] [Related]
37. Where do we stand on neuroprotection? Where do we go from here?
Shoulson I
Mov Disord; 1998; 13 Suppl 1():46-8. PubMed ID: 9613718
[TBL] [Abstract][Full Text] [Related]
38. [Slowing the age-induced decline of brain function with prophylactic use of (-)-deprenyl (Selegiline, Jumex). Current international view and conclusions 25 years after the Knoll's proposal].
Miklya I
Neuropsychopharmacol Hung; 2009 Dec; 11(4):217-25. PubMed ID: 20150659
[TBL] [Abstract][Full Text] [Related]
39. Parkinson's disease: an epidemiologic method for distinguishing between symptomatic and neuroprotective treatments.
Riggs JE
Clin Neuropharmacol; 1991 Dec; 14(6):489-97. PubMed ID: 1773420
[TBL] [Abstract][Full Text] [Related]
40. Selegiline: a reappraisal of its role in Parkinson disease.
Fabbrini G; Abbruzzese G; Marconi S; Zappia M
Clin Neuropharmacol; 2012; 35(3):134-40. PubMed ID: 22592509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
